HAYWARD, Calif., May 02, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has set the record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock"), as of
HAYWARD, Calif., April 24, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript March 28, 2024 Pulse Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Pulse Biosciences Fourth Quarter 2023 Earnings Conference Call. At this time, all […]